The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
 
Laura S. Samples
No Relationships to Disclose
 
Hossein Sadrzadeh
No Relationships to Disclose
 
Matthew J. Frigault
Consulting or Advisory Role - Arcellx; Bristol-Myers Squibb; CytoAgents; ImmPACT Bio; Iovance Biotherapeutics; Kite/Gilead; Novartis
Research Funding - Kite/Gilead; Novartis
 
Caron Alyce Jacobson
Honoraria - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instil Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Consulting or Advisory Role - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instil Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Research Funding - Kite, a Gilead company; Pfizer
 
Mehdi Hamadani
Honoraria - Celgene
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Caribou Biosciences; crispr therapeutics; Gamida Cell; Genentech; Genmab; Incyte; Kite/Gilead; MorphoSys; Myeloid Therapeutics; Novartis; Omeros; Puma Biotechnology (I); Sanofi; Seagen; Verastem
Speakers' Bureau - ADC Therapeutics; AstraZeneca; BeiGene; Genzyme; Kite/Gilead
Research Funding - Astellas Pharma; Genzyme; Genzyme; Otsuka; Spectrum Pharmaceuticals; Takeda
 
Ashwath Gurumurthi
No Relationships to Disclose
 
Paolo Strati
Consulting or Advisory Role - ADC Therapeutics; Genentech/Roche; TG Therapeutics
Research Funding - ALX Oncology; AstraZeneca
 
Roni Shouval
Consulting or Advisory Role - Medexus Pharmaceuticals; MyBiotics
 
Peter A. Riedell
Honoraria - Novartis
Consulting or Advisory Role - Abbvie; ADC Therapeutics; BeiGene; Bristol-Myers Squibb; CVS Caremark; Genmab; Intellia Therapeutics; Janssen; Kite/Gilead; Nektar; Novartis; Nurix; Pharmacyclics; Sana Biotechnology; Takeda
Speakers' Bureau - Kite/Gilead
Research Funding - Bristol-Myers Squibb; Calibr; Fate Therapeutics; Kite/Gilead; MorphoSys; Novartis; Tessa Therapeutics; Xencor
 
Saurabh Dahiya
Consulting or Advisory Role - Kite/Gilead
 
Jean Yared
Consulting or Advisory Role - Kadmon; Omeros
 
Michael D. Jain
Consulting or Advisory Role - Bristol-Myers Squibb; Kite/Gilead; Myeloid Therapeutics; Novartis
Research Funding - Incyte; Kite/Gilead
Travel, Accommodations, Expenses - Kite/Gilead
 
Frederick L. Locke
Consulting or Advisory Role - A2 Biotherapeutics; Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Caribou Biosciences; Celgene; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Miltenyi Biotec; Novartis; Sana Biotechnology; Takeda; Takeda; Umoja Biopharma; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Kite, a Gilead company
 
Lori Ann Leslie
Consulting or Advisory Role - Abbvie; AstraZeneca/Merck; BeiGene; Celgene/Bristol-Myers Squibb; Epizyme; Janssen/Pharmacyclics; Kite/Gilead; Lilly; Merck; Seagen; TG Therapeutics
Speakers' Bureau - Abbvie; AstraZeneca; BeiGene; Celgene; Epizyme; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Lilly; Pharmacyclics; Seagen; TG Therapeutics
 
Narendranath Epperla
Honoraria - Genzyme
Consulting or Advisory Role - Beigene; Karyopharm Therapeutics; Novartis; TG therapeutics
Speakers' Bureau - Incyte
Research Funding - AstraZeneca; Secura Bio
 
Monalisa Ghosh
Research Funding - Celgene (Inst); Novartis (Inst)
 
Alan Skarbnik
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; AstraZeneca; BeiGene; Curio Science; Elsevier; Epizyme; Genentech; Genmab; Janssen; Kite, a Gilead company; Lilly; MorphoSys; Novartis; Pharmacyclics; TG Therapeutics
Speakers' Bureau - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Celgene; Genentech; Janssen; Jazz Pharmaceuticals; Kite, a Gilead company; Pharmacyclics; TG Therapeutics
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Epizyme; Pharmacyclics/Janssen
 
Brian T Hill
Honoraria - Abbvie; AstraZeneca; Bayer; BeiGene; Celgene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis; Novartis; Pfizer; Pharmacyclics
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Genentech (Inst); Karyopharm Therapeutics (Inst); Kite/Gilead (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Manali K. Kamdar
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Genentech/Roche; Syncopation Life Sciences
Speakers' Bureau - Seagen
Research Funding - Novartis
 
Mazyar Shadman
Employment - Bristol-Myers Squibb (I)
Consulting or Advisory Role - Abbvie; Adaptimmune; Adaptive Biotechnologies; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Cellectar; Epizyme; Fate therapeutics; Genentech; Innate Pharma; Kite, a Gilead company; Lilly; MEI Pharma; MorphoSys; MustangBio; Pharmacyclics; Regeneron; Sound Biologics; TG Therapeutics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene; Celgene (Inst); Genentech (Inst); Genmab (Inst); Merck (Inst); MustangBio (Inst); Pharmacyclics (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst); Vincerx Pharma (Inst)